ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Clinical trial NCT07247097 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07247097
Sponsor: Massachusetts General Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Newly Diagnosed Multiple Myeloma Transplant Ineligible Newly Diagnosed Multiple Myeloma (NDMM)

Start date: 2026-08-01
Primary completion: 2030-12-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.